Erasca (ERAS) · ERAS-0015
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2027
In addition, we anticipate the initiation of monotherapy expansion cohorts and combination dose escalation cohorts as part of the AURORAS-1 trial in the second half of 2026, with associated data readouts planned for 2027.
· filed · SEC filing
After
Stated timing: H1 2027
Additional ERAS-0015 monotherapy and combination data expected in H1 2027
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/ERAS-eras-0015-2026-08-11, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/ERAS-eras-0015-2026-08-11
Erasca (ERAS) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.